科創新源(300731.SZ)股東丁承擬清倉減持不超2.13%股份
格隆匯1月3日丨科創新源(300731.SZ)公佈,股東丁承不是公司的控股股東、實際控制人,此次減持計劃實施不會影響公司治理結構和持續經營,不會導致公司控制權發生變更。
持公司股份265.9224萬股(佔公司總股本比例2.13%)的股東丁承計劃自公告發布之日起15個交易日後6個月內(即2020年1月31日至2020年7月30日)以集中競價或大宗交易方式減持公司股份不超過265.9224萬股(佔公司總股本比例2.13%,若計劃減持期間貴司有送股、資本公積金轉增股本、回購註銷等股份變動事項,則對上述股份數量進行相應調整)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.